, /PRNewswire/ -- . , a healthcare innovation campus in , and , an organization committed to advancing science and technology for the benefit of society, today announced an exciting two-part science technology seminar: and . Thought leaders in artificial intelligence and biopharmaceuticals will share their insights on how AI and machine learning accelerate target identification, predict compound interactions, and optimize clinical trial designs.
Attendees will gain valuable perspectives on the potential for AI to drive personalized medicine and tackle rare diseases, among other potential applications. Event Details for Speakers: Opening remarks will be made by , PhD, President and CEO, The New York Academy of Sciences, and the seminar will be moderated by , CEO of Cure. "AI-driven drug discovery is poised to revolutionize the biopharmaceutical industry by enhancing drug development efficiency, accuracy, and cost-effectiveness," said .
"These technological advancements promise to bring more effective treatments to patients faster, marking a significant milestone in modern medicine and public health." With only about 10 percent of drug candidates making it through a typical development time of 12 to 18 years, the ability of AI and ML tools to optimize discovery has become an area of intense interest. The influx of substantial financial commitments from private and public sectors drives new collaborations and innovations.
"Our goal is to showcase real world examples from biotech.